



1-4-02

GP 1642
#4

Docket No. 3479-4000US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Yukio Kawamura et al.

Group Art Unit: 1642

Serial No.: 09/911,969

Examiner: To be assigned

Filed: July 24, 2001

For: ANTITUMOR PROTEIN AND GENE ENCODING SAME

TECH CENTER 1600/2900

JAN 08 2002

RECEIVED

EXPRESS MAIL CERTIFICATE

Express Mail Label No.: EL 853248895 US

Date of Deposit: November 9, 2001

I hereby certify that the following attached paper(s) and/or fee

1. Transmittal of Letter Requesting Transfer of the Computer Readable Form of the Sequence Listing Filed in Parent Application 09,023,731, now US Patent No. 6,291,648 B1
2. Letter Requesting Transfer of the Computer Readable Form of the Sequence Listing Filed in Parent Application 09,023,731, now US Patent No. 6,291,648 B1.
3. Copy of Notice to Comply.
4. Return receipt postcard.

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Arline E. Walz

(Typed or printed name of person mailing papers(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



Docket No. 3479-4000US1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Kawamura et al.

Group Art Unit: 1642

Serial No.: 09/911,969

Examiner: To be assigned

Filed: July 24, 2001

For: ANTITUMOR PROTEIN AND GENE ENCODING SAME

TECH CENTER 1600/2900

JAN 08 2002

RECEIVED

**TRANSMITTAL OF LETTER REQUESTING TRANSFER OF THE COMPUTER
READABLE FORM OF THE SEQUENCE LISTING FILED IN
PARENT APPLICATION 09,023,731, NOW US PATENT NO. 6,291,648 B1**

Commissioner for Patents
Washington, D.C. 20231

Sir:


Transmitted herewith is/are the following items for the above-identified application:

- ☒ Letter Requesting Transfer of the Computer Readable Form of the Sequence Listing Filed in Parent Application 09,023,731, now US Patent No. 6,291,648 B1
- ☒ Copy of Notice to Comply
- ☒ Return receipt Postcard
- ☐ Please charge the required fee of \$_____ to Deposit Account No. 13-4500, Order No. . . .
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3479-4000US1. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.

Dated: November 9, 2001

By:


Kenneth H. Sonnenfeld
Registration No. 33,285

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



PATENT
Docket No.: 3479-4000US1

TECH CENTER 1600/2900

JAN 08 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Kawamura et al. Group Unit: 1642
Serial No. : 09/911,969 Examiner: To Be Assigned
Filed : July 24, 2001
For : ANTITUMOR PROTEIN AND GENE ENCODING SAME

Commissioner for Patents
Washington, D.C. 20231
Attn: Box Application

**LETTER REQUESTING TRANSFER OF THE COMPUTER
READABLE FORM OF THE SEQUENCE LISTING FILED IN
PARENT APPLICATION 09,023,731, NOW US PATENT NO. 6,291,648 B1**

The paper copy of the Sequence Listing in this application, 09/922,969, is identical to the computer readable copy of the Sequence Listing filed in application 09,023,731, now US Patent No. 6,291,648 B1, filed February 13, 1998. In accordance with 37 CFR 1.82(e), please use the only computer-readable form filed in that application as the computer readable form for the instant application. It is understood that the Patent and Trademark Office will make the necessary change in application number and filing date for the instant application. A paper copy of the Sequence Listing is included in the originally-filed specification of the instant application.


AUTHORIZATION

The Commissioner is hereby authorized to charge any additional fees which may be required for timely consideration of this Amendment under 37 C.F.R. §§1.16 -§1.20 or credit any overpayment to Deposit Account No. 13-4500, Order No. 3479-4000US1. A
DUPLICATE COPY OF THIS PAGE IS ATTACHED.

Respectfully submitted,


MORGAN & FINNEGAN, L.L.P.

Dated: November 9, 2000

By: 
Kenneth H. Sonnenfeld
Registration No.: 33,285

Mailing Address:

MORGAN & FINNEGAN, L.L.P
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849 Telecopier



RECEIVED
JAN 08 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/911,969	07/24/2001	Yukio Kawamura	3479-4000US1

CONFIRMATION NO. 4744

FORMALITIES LETTER



OC000000006554118

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053

Date Mailed: 09/14/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

CASE 3479-4000US1 ATTY SAL

DUE DATE November 14, 2001

STATUTORY DATE April 14, 2002

BY J.M.

A copy of this notice **MUST** be returned with the reply.

MORGAN & FINNEGAN LLP

2001 SEP 20 PM 4:18

RECEIVED
DOCKET DEPT.

AA
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY
